Clive Dilworth
Director of Scientific Operations (UK),
Cyprotex
Biography
Clive Dilworth is the Director of Scientific Operations at Cyprotex providing scientific leadership to the Company.s staff, operational leadership to staff performing work for customers, scientific support to the business development/marketing function and direction of new business initiatives from a scientific perspective. Prior to this position Clive was the Senior Principal Scientist at Cyprotex where his responsibilities included driving the development of new assays including the recent in vitro toxicity developments, overseeing the ongoing ADME client studies and responsible for the scientific development and promotion of Cyprotex externally. Previously Clive held positions at Quintiles, Aventis and GSK where his work focused on in vitro drug metabolism, and in vitro models of hepatotoxicity. Clive completed his PhD at the University of London (School of Pharmacy) investigating early markers of in vitro toxicity in hepatic cell models under the supervision of Professor John Timbrell.
ADME training course objective
This course is designed for personnel in the pharmaceutical and biotechnology industries and contract research organisations who want to understand the rationale, methodology and importance of in vitro ADME and DMPK studies during the drug discovery and development processes. This course is focused at individuals within industry wanting to expand their knowledge of in vitro ADME and DMPK for example, medicinal chemists wishing to understand the importance of early ADME testing or project managers wanting to understand the DMPK profile of lead compounds.
The various types of in vitro ADME and DMPK studies will be discussed detailing the benefits of performing these assays early in drug discovery, an overview of the methodologies currently available and how these data can be used to make informed decisions based upon a compounds overall ADME/DMPK profile.
